title: Substance use and psychosocial outcomes following participation in residential laboratory studies of marijuana, methamphetamine and zolpidem.
abstract: BACKGROUND
  Non-therapeutic research with drugs of abuse in humans is important for a more comprehensive understanding of substance abuse and for the development of more effective treatments. However, the administration of substances from drug classes with abuse potential to human volunteers raises ethical questions regarding potential risk to study volunteers.
  
  
  OBJECTIVE
  The purpose of this study was to assess the psychosocial functioning and reported drug-taking behavior of volunteers before and after participating in a residential laboratory study, during which either marijuana, methamphetamine or zolpidem was administered.
  
  
  METHODS
  Twenty-two volunteers were administered Addiction Severity Index (ASI) interviews at intake and approximately six months following their study participation.
  
  
  RESULTS
  No significant differences between intake and follow-up assessments were found on any ASI composite or drug/alcohol-taking variable.
  
  
  CONCLUSIONS
  These preliminary data suggest that participation in residential laboratory studies involving the administration of drugs from classes with abuse potential does not alter subsequent psychosocial functioning or reported drug use.
authors.affiliation: Columbia University, New York, New York, USA. npv2101@columbia.edu
authors.forename: Nehal P
authors.initials: NP
authors.lastname: Vadhan
authors.forename: Carl L
authors.initials: CL
authors.lastname: Hart
authors.forename: Brooke
authors.initials: B
authors.lastname: Roe
authors.forename: Jana
authors.initials: J
authors.lastname: Colley
authors.forename: Margaret
authors.initials: M
authors.lastname: Haney
authors.forename: Richard W
authors.initials: RW
authors.lastname: Foltin
mesh_terms: D000437:Alcoholism / Q000191:economics / Q000523:psychology / Q000534:rehabilitation; D003365:Costs and Cost Analysis; D015259:Dopamine Agents / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D006993:Hypnotics and Sedatives / Q000191:economics / Q000627:therapeutic use*; D002189:Marijuana Abuse / Q000191:economics / Q000523:psychology* / Q000534:rehabilitation*; D008694:Methamphetamine / Q000191:economics / Q000627:therapeutic use*; D009518:New York; D011725:Pyridines / Q000191:economics / Q000627:therapeutic use*; D012944:Social Support; D019966:Substance-Related Disorders / Q000191:economics / Q000523:psychology* / Q000534:rehabilitation*; D016896:Treatment Outcome; D000077334:Zolpidem
chemical_list: D015259:Dopamine Agents; D006993:Hypnotics and Sedatives; D011725:Pyridines; D008694:Methamphetamine; D000077334:Zolpidem